|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
In this Review, we provide the latest insights into the complexity and interplay of the components of the non-canonical renin-angiotensin system, and discuss the function and therapeutic potential of targeting this system to treat cardiovascular disease.
|
31427727 |
2020 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
As a counter-regulatory arm of the renin angiotensin system (RAS), the angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS axis (ACE2-Ang-(1-7)-MAS axis) plays a protective role in cardiovascular diseases.
|
31359146 |
2020 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Current cardiovascular pharmacotherapy targets maladaptive overactivation of the renin-angiotensin-aldosterone system (RAAS), which occurs throughout the continuum of cardiovascular disease spanning from hypertension to heart failure with reduced ejection fraction.
|
31786973 |
2020 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Activation of renin-angiotensin- system, nitric oxide (NO•) bioavailability and subsequent sympathoexcitation plays a pivotal role in the pathogenesis of many cardiovascular diseases, including hypertension.
|
31654775 |
2020 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Previous studies indicate that perinatal compromise of taurine causes cardiovascular disorders in adults via the influence of taurine on renin-angiotensin system (RAS).
|
31468385 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
It is known that the renin-angiotensin system plays a major role in the pathophysiology of cardiovascular disease and renal injury.
|
31141400 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
While the REN promoter is isolated from neighboring super-enhancers in most cells by insulators, these insulators break down with cell age to permit the inappropriate expression of REN in non-kidney cells by using the neighboring super-enhancers, resulting in expression in a wider spectrum of tissues, contributing to aging-related immune system dysregulation, cardiovascular diseases and cancers.
|
31520345 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
<b>Abbreviations</b>: Angiotensin-converting enzyme (ACE); Angiotensin converting enzyme inhibitors (ACEIs); Angiotensin II (ANG II); Analysis of variance (ANOVA); Angiotensin receptor blockers (ARBs); Blood Pressure (BP); Calcium Antagonists Calcium Channel Blockers (CCB); Chronic kidney diseases (CKD); Sodium carboxyl methyl cellulose (CMC-Na); Cardiac mass index (CMI); Cardiovascular diseases (CVD); Diastolic blood pressure (DBP); Enzyme-linked immunosorbent assay (ELISA); Hematoxylin-eosin (H&E); Kidney mass index (KMI); Liver mass index (LMI); Mean arterial blood pressure (MAP); Plasma renin concentration (PRC); Renin-angiotensin system (RAS); Rennin (REN); Systolic blood pressure (SBP); Student-Newman-Keuls q test (SNK-q test); Spontaneous hypertension rats (SHR); Valsartan asleep Administration (VSA); Valsartan awake Administration (VWA); Wistar-Kyoto (WKY); Mesor (M); Amplitude (A); Phase (φ).
|
31096810 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Presented herein, evidence in literature in support of a cross-talk between the renin-angiotensin system (RAS) and sympathetic nervous system (SNS), both known to be involved in the development of hypertension and cardiovascular disease, and as one of the underlying mechanisms of SUDEP.
|
31565791 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The most frequent association observed among CVD preventive treatment was agents acting on the renin-angiotensin system and lipid-lowering drugs (5.1% of treated subjects).
|
30987984 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Obesity may compound the increased risk of hypertension and cardiovascular disease in individuals born prematurely by further augmenting the prematurity-associated imbalance in the renin-angiotensin system.
|
30404738 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Both hyperuricemia and adipose tissue renin-angiotensin system (RAS) are closely associated with multiple metabolic and cardiovascular diseases.
|
31002842 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
(Pro)renin receptor (PRR), a novel member of the renin-angiotensin system, participates in various cardiovascular diseases.
|
31498445 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Classic drugs, such as those targeting renin-angiotensin-aldosterone system, statins and aspirin remain first-line treatment options, both for primary and secondary prevention of CVD.
|
31262142 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Despite the success of renin-angiotensin system (RAS) blockade by angiotensin-converting enzyme (ACE) inhibitors and angiotensin II type 1 receptor (AT<sub>1</sub>R) blockers, current therapies for hypertension and related cardiovascular diseases are still inadequate.
|
31537750 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Previously, the inhibition of neurohormonal systems, namely the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system, has proven to be useful in the treatment of many CVDs.
|
31035359 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The exact mechanisms of how fetal programming events increase the risk of hypertension and cardiovascular disease are not fully elaborated; however, the focus on alterations in the biochemical components and functional aspects of the renin-angiotensin (Ang) system (RAS) has predominated, particularly activation of the Ang-converting enzyme (ACE)-Ang II-Ang type 1 receptor (AT<sub>1</sub>R) axis.
|
30622158 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent Advances in the Knowledge of Naturally-derived Bioactive Compounds as Modulating Agents of the Renin-angiotensin-aldosterone System: Therapeutic Benefits in Cardiovascular Diseases.
|
30931846 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Activation of the renin-angiotensin system (RAS) plays a pivotal role in mediating hypertension, chronic kidney and cardiovascular diseases.
|
30710617 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
CVD have been associated with important changes in systemic and tissue Renin-Angiotensin System (RAS).
|
31849284 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The renin-angiotensin-aldosterone system (RAAS) is associated with renal and cardiovascular disease in diabetes.
|
30799029 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
We considered antihypertensive therapy and lipid-lowering therapy to be optimal when known patients with hypertension with albuminuria received renin-angiotensin system blockers and statins had been prescribed for overt cardiovascular disease.
|
31542750 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The (pro)renin receptor [(P)RR)] is involved in the activation of local renin-angiotensin system and subsequent development of cardiovascular disease.
|
30769036 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The (pro)renin receptor (PRR) is an important member of the local tissue renin-angiotensin system and plays a vital role in many cardiovascular diseases.
|
31049135 |
2019 |
|
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Activation of the renin-angiotensin system (RAS) contributes to the pathogenesis of cardiovascular diseases.
|
31636805 |
2019 |